This issue of The Teal Journal brings a new look and a new spotlight on survivorship—as well as the reports you love on ground-breaking research and the happenings on Capitol Hill.
In this issue, we discuss the pending “fiscal cliff” and what it could mean for cancer research if Congress doesn’t act. We look at research exploring two ways of using folate receptors in treatment of ovarian cancer; as this issue went to press we learned that one company has applied for approval to use a folate receptor drug in the European Union. Alice Spinelli, a nurse practitioner specializing in gynecologic cancers, answers questions about how ovarian cancer research advanced in 2012. In a new feature, long-term survivor Joan Sommer shares her story and some tips for coping with ovarian cancer recurrence.
Chief Executive Officer
The Ovarian Cancer National Alliance